Related Experiment Videos
Complement in hematological neoplasias
Allergologia Et Immunopathologia
|January 1, 1979
Summary
Complement levels (CH50) were elevated in most hematological neoplasias, particularly Hodgkin's disease and acute leukemia, suggesting a role for complement in these cancers.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- The complement system is crucial in immune responses.
- Alterations in complement may be linked to neoplastic diseases.
Purpose of the Study:
- To investigate complement system component levels in various hematological malignancies.
- To explore potential correlations between complement activation and cancer progression.
Main Methods:
- Quantification of total hemolytic complement (CH50) using a modified Kabat and Mayer method.
- Measurement of eight complement antigenic fractions (C1q, C1s, C3, C4, C5, INHC1, C3A, properdin) via Manani and Laurell's techniques.
- Analysis of complement levels in 30 patients across non-Hodgkin's lymphomas, chronic lymphocytic leukemia, Hodgkin's disease, acute leukemia, chronic myeloid leukemia, and multiple myeloma.
Main Results:
- Significant increases in CH50 were observed in Hodgkin's disease, acute leukemia, and chronic myeloid leukemia.
- Elevated levels of C1s, C3, C4, C5, C9, and C3A were noted in specific hematological neoplasia groups.
- No significant variations in C1s, INHC1, and properdin were found across the studied groups.
- No correlation was established between the clinical course of the disease and complement levels.
Conclusions:
- The complement system shows significant activation in various hematological malignancies.
- Specific complement components may serve as potential biomarkers for certain cancers.
- Further research is warranted to elucidate the precise role of complement in neoplastic disease pathogenesis.